$內克塔治療(NKTR.US)$Nektar Therapeutics:Received Letter From Nasdaq Notifying Co It Regained Compliance With Minimum Bid Price Requirement for Continued Listing on Nasdaq
$內克塔治療(NKTR.US)$• Nektar Therapeutics has regained full rights to its drug candidate REZPEG and is advancing Phase 2b studies for atopic dermatitis and alopecia areata. • The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025. • Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75...
Nektar Therapeutics' CEO, Howard Robin, is pleased with the deal, stating it strengthens the company's finances and extends its cash runway to Q3 2026. He also emphasized the potential of rezpegaldesleukin, a novel biologic in Phase 2b studies.
$內克塔治療(NKTR.US)$Nektar Therapeutics Reports Positive Preclinical Data on NKTR-255 MT Newswires· 1 min ago Nektar Therapeutics (NKTR) said Monday that new preclinical data on NKTR-255 showed that a combination of the product candidate with obinutuzumab "significantly enhanced" the cytotoxicity of expanded Natural Killer or NK cells against rituximab-resistant Burkitt Lymphoma cells. "Preclinical and early clinical data suggest that NKTR-255 can improve proliferation and pers...
$內克塔治療(NKTR.US)$Nektar Presents New Responder Data For Rezpegaldesleukin, A First-In-Class Selective Regulatory T-cell Therapy, In Late-Breaking News Oral Presentation At 2023 EADV Congress Benzinga· 1 min ago – Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rapid Onset of Action and Continuing Benefit for 36 Weeks After 12-Week Treatment Period – – New Data Presented Show Encouraging Proportion of Patient-Reported Responder Outcomes for DLQ...
內克塔治療股票討論區
• The company's TNFR2 agonist antibody, NKTR-0165, targets autoimmune diseases and is slated for clinical trials in the first half of 2025.
• Nektar ended the year with $329.4 million in cash and investments and expects 2024 revenues of $75...
MT Newswires· 1 min ago
Nektar Therapeutics (NKTR) said Monday that new preclinical data on NKTR-255 showed that a combination of the product candidate with obinutuzumab "significantly enhanced" the cytotoxicity of expanded Natural Killer or NK cells against rituximab-resistant Burkitt Lymphoma cells.
"Preclinical and early clinical data suggest that NKTR-255 can improve proliferation and pers...
Benzinga· 1 min ago
– Dose-Dependent Efficacy Reported Across All Endpoints for REZPEG Demonstrating a Rapid Onset of Action and Continuing Benefit for 36 Weeks After 12-Week Treatment Period –
– New Data Presented Show Encouraging Proportion of Patient-Reported Responder Outcomes for DLQ...
暫無評論